# Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia

> **NCT01371630** · PHASE1,PHASE2 · RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 276 (estimated)

## Conditions studied

- B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
- B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
- Burkitt-Like Lymphoma With 11q Aberration
- High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements
- High Grade B-Cell Lymphoma, Not Otherwise Specified
- Recurrent B Acute Lymphoblastic Leukemia
- Recurrent Burkitt Lymphoma
- Refractory B Acute Lymphoblastic Leukemia
- Refractory Burkitt Lymphoma

## Interventions

- **BIOLOGICAL:** Blinatumomab
- **DRUG:** Cyclophosphamide
- **DRUG:** Cytarabine
- **DRUG:** Dexamethasone
- **BIOLOGICAL:** Inotuzumab Ozogamicin
- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Mercaptopurine
- **DRUG:** Methotrexate
- **DRUG:** Prednisone
- **BIOLOGICAL:** Rituximab
- **DRUG:** Vincristine

## Key facts

- **NCT ID:** NCT01371630
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2011-08-26
- **Primary completion:** 2027-12-25
- **Final completion:** 2027-12-25
- **Target enrollment:** 276 (ESTIMATED)
- **Last updated:** 2025-12-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01371630

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01371630, "Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01371630. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*